NeoImmuneTech Inc - Korean Depository Re

1
XKRX:950220 (USA)   Korean Depository Receipts
â‚© 1895.00 (-0.26%) May 23
At Loss
P/B:
0.50
Market Cap:
â‚© 37.47B ($ 27.39M)
Enterprise V:
â‚© -27.69B ($ -20.24M)
Volume:
923.27K
Avg Vol (2M):
1.33M
Volume:
923.27K
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for NeoImmuneTech Inc ( XKRX:950220 ) from 2021 to May 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. NeoImmuneTech stock (XKRX:950220) PE ratio as of May 23 2024 is 0. More Details

NeoImmuneTech Inc (XKRX:950220) PE Ratio (TTM) Chart

To

NeoImmuneTech Inc (XKRX:950220) PE Ratio (TTM) Historical Data

Total 817
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10
NeoImmuneTech PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-23 At Loss 2024-03-15 At Loss
2024-05-22 At Loss 2024-03-14 At Loss
2024-05-21 At Loss 2024-03-13 At Loss
2024-05-20 At Loss 2024-03-12 At Loss
2024-05-17 At Loss 2024-03-11 At Loss
2024-05-16 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-02-29 At Loss
2024-05-07 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-08 At Loss
2024-04-16 At Loss 2024-02-07 At Loss
2024-04-15 At Loss 2024-02-06 At Loss
2024-04-12 At Loss 2024-02-05 At Loss
2024-04-11 At Loss 2024-02-02 At Loss
2024-04-09 At Loss 2024-02-01 At Loss
2024-04-08 At Loss 2024-01-31 At Loss
2024-04-05 At Loss 2024-01-30 At Loss
2024-04-04 At Loss 2024-01-29 At Loss
2024-04-03 At Loss 2024-01-26 At Loss
2024-04-02 At Loss 2024-01-25 At Loss
2024-04-01 At Loss 2024-01-24 At Loss
2024-03-29 At Loss 2024-01-23 At Loss
2024-03-28 At Loss 2024-01-22 At Loss
2024-03-27 At Loss 2024-01-19 At Loss
2024-03-26 At Loss 2024-01-18 At Loss
2024-03-25 At Loss 2024-01-17 At Loss
2024-03-22 At Loss 2024-01-16 At Loss
2024-03-21 At Loss 2024-01-15 At Loss
2024-03-20 At Loss 2024-01-12 At Loss
2024-03-19 At Loss 2024-01-11 At Loss
2024-03-18 At Loss 2024-01-10 At Loss

NeoImmuneTech Inc (XKRX:950220) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

NeoImmuneTech Inc
NAICS : 541714 SIC : 2834
ISIN : KR8840140006

Share Class Description:

XKRX:950220: Korean Depository Receipts
Description
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.